Patents by Inventor André Pelegrin

André Pelegrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11001634
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 11, 2021
    Assignees: GAMAMABS PHARMA, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
  • Patent number: 10385137
    Abstract: The invention concerns antibody formats comprising VH sequence of Camelidae, such as llamas; antibodies of various formats have anti-CEA or anti-CD16 VH sequences thereof; vectors expressing the antibody formats, and methods for producing the same.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: August 20, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique (CNRS), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val D'Aurelle, Institut Paoli Calmettes
    Inventors: Daniel Baty, Ghislaine Behar, Martine Mansais, Andre Pelegrin, Jean-luc Teillaud, Isabelle Teulon
  • Publication number: 20190153104
    Abstract: The present disclosure relates to bispecific antibodies targeting EGFR and HER2, and methods for the production of these antibodies. The bispecific antibodies consist of one complete antibody on which two VH-VL chains are attached via a linker to each NH terminal region of both VH chains of the antibody. The bispecific antibodies constructed use the amino acid sequences of the heavy chain (VH) and the light chain (VL) variable regions of two monoclonal antibodies targeting EGFR and HER2, namely cetuximab and trastuzumab, respectively.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 23, 2019
    Inventors: EUGENE ZHUKOVSKY, OLIVIER LEGER, PIERRE-EMMANUEL GERARD, ANDRE PELEGRIN, CHRISTEL LARBOURET
  • Patent number: 10196455
    Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: February 5, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: Thierry Chardes, Nadege Gaborit, Christel Larbouret, Andre Pelegrin
  • Publication number: 20180291098
    Abstract: The disclosure relates to human anti-NRG1 neutralizing monoclonal antibodies that do not interfere with the NRG1 binding to the HER3 receptor and uses thereof. More particularly, an isolated human monoclonal antibody comprising a heavy and light chain variable regions with specific CDRs defined by their sequences is disclosed.
    Type: Application
    Filed: October 26, 2016
    Publication date: October 11, 2018
    Inventors: Charline Ogier, Christel Larbouret, Andre Pelegrin, Thierry Chardes
  • Publication number: 20180155433
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Application
    Filed: May 2, 2016
    Publication date: June 7, 2018
    Inventors: Thierry CHARDÈS, Olivier DUBREUIL, André PELEGRIN, Christel LARBOURET, Jean-François PROST, Jean-Marc BARRET, Stéphane DEGOVE
  • Patent number: 9522956
    Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: December 20, 2016
    Assignee: L'Institut National de la Sante et de la Recherche Medicale
    Inventors: Stephen D. Gillies, David Azria, Christel Larbouret, André Pelegrin
  • Publication number: 20160319033
    Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.
    Type: Application
    Filed: November 7, 2013
    Publication date: November 3, 2016
    Inventors: Thierry Chardes, Nadege Gaborit, Christel Larbouret, Andre Pelegrin
  • Patent number: 9458239
    Abstract: The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: October 4, 2016
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Isabelle Teulon, André Pelegrin
  • Patent number: 9409988
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 9, 2016
    Assignees: INSERM (Institut National De La Sante Et De La Recherche Medicale), ORIBASE Pharma, UNIVERSITE De Montpellier 1, INSTITUT Regional Du Cancer De Montpellier-Val D'Aurelle
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • Patent number: 9346883
    Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 24, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Gamamabs Pharma SA
    Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
  • Publication number: 20160083476
    Abstract: The invention concerns antibody formats comprising VHsequence of Camelidae, such as llamas; antibodies of various formats have anti-CEA or anti-CD16 VH sequences thereof; vectors expressing the antibody formats, and methods for producing the same.
    Type: Application
    Filed: September 16, 2015
    Publication date: March 24, 2016
    Inventors: Daniel Baty, Ghislaine Behar, Martine Chartier, Andre Pelegrin, Jean-luc Teillaud, Isabelle Teulon
  • Patent number: 9249228
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: February 2, 2016
    Assignees: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • Patent number: 9169316
    Abstract: The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: October 27, 2015
    Assignees: Centre National de la Recherche Scientifique-CNRS, INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val d'Aurelle, Institut Paoli Calmettes
    Inventors: Daniel Baty, Ghislaine Behar, Martine Chartier, André Pelegrin, Jean-luc Teillaud, Isabelle Teulon
  • Patent number: 9127065
    Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Val d'Aurelle—Paul Lamarque, Universite de Montpellier 1
    Inventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
  • Publication number: 20150132308
    Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Stephen D. Gillies, David Azria, Christel Larbouret, André Pelegrin
  • Publication number: 20140302041
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 9, 2014
    Applicants: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • Publication number: 20140227283
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.
    Type: Application
    Filed: June 22, 2012
    Publication date: August 14, 2014
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Regional du Cancer de Montpellier-Val d'Aurelle, UNIVERSITE DE MONTPELLIER 1, OriBase Pharma
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • Publication number: 20140141019
    Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 22, 2014
    Applicant: INSERM (INSTITUT NATIONALDE LA SENTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
  • Publication number: 20140112931
    Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.
    Type: Application
    Filed: May 21, 2012
    Publication date: April 24, 2014
    Applicants: UNIVERSITE DE MONTPELLIER 1, CENTRE VAL D'AURELLE - PAUL LAMARQUE
    Inventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek